Olivia Esposito • November 30, 2023
Reasonable Accommodations

Through collaboration with Reasonable Accommodations LLC, the HCMA has expanded some of our COE directories. This expansion will make it easier to find travel information, places to eat, lodgings, etc. Only a handful of COE directories have been updated so far, in 2024 we plan on populating the rest. 

You can check out the new expanded directories using the links below.  

Allegheny General Hospital- https://4hcm.org/agh/

Cleveland Clinic – https://4hcm.org/cleveland1/

Cleveland Clinic Children’s – https://4hcm.org/cleveland2/

Columbia University Hypertrophic Cardiomyopathy Center – https://4hcm.org/columbia/

Corewell Health – https://4hcm.org/corewell/

Mayo Clinic – https://4hcm.org/mayo/

NYU Langone Health – https://4hcm.org/langone/

The Christ Hospital- https://4hcm.org/christhosp/

We would love some feedback on these expansions. 

HCMA Blog

Pro Publica Releases Results of FDA Investigation

By Erica Friedman • June 26, 2025
Investigative journalists Debbie Cenziper, Megan Rose, Brandon Roberts and Irena Hwang from Pro Publica and NPR have concluded a 14-month long investigation into the quality of generic drugs coming into the United States from overseas. Among the many voices that spoke up for American patients was HCMA Founder and CEO, Lisa Salberg who has felt the effects of low-quality drugs personally. Salberg believes that fixing this problem is something we can do, even in this time, when even health care is highly politicized. Read the key takeaways from ProPublica’s 14-month investigation into the FDA’s oversight of foreign drugmakers in Threat in Your Medicine Cabinet: The FDA’s Gamble on America’s Drugs .
A light blue and dark blue paintbrush stroke intersect to make a stylized

Alnylam Receives European Commission Approval for AMVUTTRA® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy (ATTR-CM)

By Erica Friedman • June 18, 2025
Alnylam press release on the European Commission approval of AMVUTTRA® (vutrisiran) forwild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM) as an additional indication
Light & dark blue brush stroke that intersect create an abstract letter 'a' next to the word Alnylam

Alnylam Announces FDA Approval of AMVUTTRA® (vutrisiran) for Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM)

By Erica Friedman • June 17, 2025
AMVUTTRA® (vutrisiran) has been approved by the U.S. Food and Drug Administration (FDA) to treat ATTR-CM in adults.
More Posts